Swiss National Bank cut its stake in Spark Therapeutics, Inc. (NASDAQ:ONCE) by 0.3% during the third quarter, Holdings Channel reports. The fund owned 36,500 shares of the company’s stock after selling 100 shares during the period. Swiss National Bank owned about 0.12% of Spark Therapeutics worth $2,192,000 as of its most recent filing with the SEC.

A number of other large investors have also recently modified their holdings of ONCE. UBS Asset Management Americas Inc. boosted its stake in shares of Spark Therapeutics by 18.2% in the third quarter. UBS Asset Management Americas Inc. now owns 174,420 shares of the company’s stock valued at $10,476,000 after buying an additional 26,909 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Spark Therapeutics by 13.3% in the third quarter. Bank of New York Mellon Corp now owns 94,284 shares of the company’s stock valued at $5,662,000 after buying an additional 11,061 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in shares of Spark Therapeutics during the third quarter valued at $28,290,000. Alps Advisors Inc. boosted its stake in shares of Spark Therapeutics by 1.4% in the third quarter. Alps Advisors Inc. now owns 39,036 shares of the company’s stock valued at $2,345,000 after buying an additional 547 shares during the last quarter. Finally, Neuberger Berman Group LLC boosted its stake in shares of Spark Therapeutics by 38.9% in the third quarter. Neuberger Berman Group LLC now owns 12,500 shares of the company’s stock valued at $751,000 after buying an additional 3,500 shares during the last quarter. 82.98% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics, Inc. (NASDAQ:ONCE) opened at 57.13 on Friday. The company’s market capitalization is $1.76 billion. Spark Therapeutics, Inc. has a one year low of $21.20 and a one year high of $65.99. The stock’s 50 day moving average price is $53.39 and its 200-day moving average price is $55.20.

Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Thursday, November 3rd. The company reported ($1.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.01) by $0.06. The firm had revenue of $1.30 million for the quarter, compared to the consensus estimate of $1.26 million. Spark Therapeutics had a negative net margin of 441.05% and a negative return on equity of 28.28%. The company’s revenue for the quarter was up .0% on a year-over-year basis. During the same period last year, the firm earned ($0.70) earnings per share. Equities analysts forecast that Spark Therapeutics, Inc. will post ($4.13) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was reported by Watch List News and is the propert of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this piece can be viewed at http://www.watchlistnews.com/swiss-national-bank-sells-100-shares-of-spark-therapeutics-inc-once/1061490.html.

Several equities research analysts recently weighed in on the company. Zacks Investment Research cut Spark Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. Jefferies Group reaffirmed a “hold” rating and issued a $57.00 price target on shares of Spark Therapeutics in a research note on Tuesday. Vetr cut Spark Therapeutics from a “buy” rating to a “hold” rating and set a $62.50 target price on the stock. in a research note on Tuesday. BMO Capital Markets assumed coverage on Spark Therapeutics in a research note on Tuesday, December 20th. They issued an “outperform” rating and a $69.00 target price on the stock. Finally, Chardan Capital reissued a “neutral” rating on shares of Spark Therapeutics in a research note on Tuesday, December 6th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the company’s stock. Spark Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $60.69.

In other Spark Therapeutics news, CEO Jeffrey D. Marrazzo sold 5,000 shares of Spark Therapeutics stock in a transaction on Monday, October 17th. The stock was sold at an average price of $54.66, for a total transaction of $273,300.00. Following the completion of the sale, the chief executive officer now directly owns 235,000 shares of the company’s stock, valued at approximately $12,845,100. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Katherine A. High sold 10,000 shares of Spark Therapeutics stock in a transaction on Monday, November 14th. The shares were sold at an average price of $60.30, for a total value of $603,000.00. Following the sale, the insider now directly owns 210,000 shares of the company’s stock, valued at $12,663,000. The disclosure for this sale can be found here. Company insiders own 9.60% of the company’s stock.

About Spark Therapeutics

Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).

5 Day Chart for NASDAQ:ONCE

Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics, Inc. (NASDAQ:ONCE).

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.